Tyalia (aflibercept biosimilar) / CinnaGen - LARVOL DELTA

Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study). (PubMed, Eye (Lond)) - "The preliminary real-world data from this limited early series suggest that Tyalia appears to have similar clinical efficacy and safety as aflibercept 2 mg innovator across the approved indications. However, long-term data with a larger population are needed to further strengthen the findings of this study."

Journal • Real-world evidence • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration